Cidara reports positive Phase 2b results for CD388; 76.1% efficacy at 450mg dose

Cidara Therapeutics, Inc.

Primary endpoint met: prevention efficacy 57.7% (150mg), 61.3% (300mg), 76.1% (450mg); all p<0.01.
All secondary endpoints met including at 37.8°C and 37.2°C temperature thresholds; PE maintained up to 28 weeks.
CD388 well-tolerated at all doses; no drug-related serious adverse events; injection site reactions similar to placebo.
Company submitted end of Phase 2 meeting request to FDA to discuss Phase 3 trial design and timelines.
Additional NAVIGATE trial results expected to be presented at scientific conferences in 2025.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.